Adjuvant chemotherapy in breast cancer.

Recent Results Cancer Res

Published: April 1982

One single course of i.v. cyclophosphamide (30 mg/kg) was given over a 6-day period to 559 mastectomized patients. During a follow-up period of up to 15 years, 241 recurrence and 234 deaths are registered in this group, and 294 recurrences and 283 deaths in the randomized control group of 577 patients. Analysis of the life-table curves shows an increased cure rate of about 10%.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-81685-7_24DOI Listing

Publication Analysis

Top Keywords

adjuvant chemotherapy
4
chemotherapy breast
4
breast cancer
4
cancer single
4
single course
4
course cyclophosphamide
4
cyclophosphamide mg/kg
4
mg/kg 6-day
4
6-day period
4
period 559
4

Similar Publications

Importance: Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic cancer, a devastating sequela with a 12- to 18-month life expectancy. Until recently, one strategy for treating early-stage triple-negative breast cancer was chemotherapy after surgery. However, it was not known whether the addition of immune therapy to postsurgery chemotherapy would be beneficial.

View Article and Find Full Text PDF

Objectives: This study was conducted to investigate whether preoperative or postoperative carcinoembryonic antigen (CEA) with a new cut-off value is more optimal for predicting long-term outcomes in patients with Stage II/III rectal cancer, and to investigate the effectiveness of postoperative adjuvant chemotherapy (POAC) based on the CEA values.

Methods: Serum CEA levels were measured preoperatively (pre-CEA) and postoperatively (post-CEA). The area under the receiver operating curve (AUROC) was used to determine a cut-off for CEA.

View Article and Find Full Text PDF

Non-small cell lung cancer (NSCLC) remains a dire disease being the first cause of cancer death among both genders. Early-stage NSCLC often has better treatment outcomes despite it being a highly heterogeneous disease. So far, the neo-adjuvant chemotherapy strategies have led to a small benefit with an improvement of 5% in overall survival as an absolute benefit.

View Article and Find Full Text PDF

Primary Renal Lymphoma: A Single-Center Study of 14 Cases.

Clin Genitourin Cancer

January 2025

Department of Pathology, The First Medical Centre, Chinese PLA General Hospital, Beijing, China. Electronic address:

Objective: To investigate the clinical characteristics, pathology, imaging features, and prognosis of primary renal lymphoma (PRL), a rare malignancy.

Patients And Method: We conducted a retrospective review of 14 PRL cases diagnosed between January 2009 and January 2022, with follow-up data collected from medical records.

Results: The study included 14 patients (7 males, 7 females), with a mean age of 60.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!